Cresset Asset Management’s RxSight RXST Stock Holding History

Cresset Asset Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-315,719	Closed	-$3.84M	–	858
2022 Q4	$3.84M	Hold	315,719	–	–	0.05%	142
2022 Q3	$3.79M	Hold	315,719	–	–	0.05%	148
2022 Q2	$4.45M	Hold	315,719	–	–	0.05%	138
2022 Q1	$3.91M	Buy	+315,719	New	+$3.79M	0.04%	154

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Cresset Asset Management's RXST Position: Q1 2023 in Review

Cresset Asset Management sold out of RxSight (RXST) in Q1 2023, closing a stake of 315,719 shares — an estimated $3.84M sold.

Cresset Asset Management first reported a position in RXST in Q1 2022 and held it in 4 quarters. The position peaked at $4.45M in Q2 2022. 74 funds tracked by Wall St. Rank hold RXST as of Q1 2023.

Cresset Asset Management reported no remaining RxSight position as of Q1 2023 after selling out during the quarter.
Cresset Asset Management sold 315,719 RxSight shares in Q1 2023, an estimated $3.84M.
Cresset Asset Management first reported a position in RxSight in Q1 2022 and held it in 4 quarters.
Cresset Asset Management's RxSight position peaked at $4.45M in Q2 2022.
74 funds tracked by Wall St. Rank held RxSight as of Q1 2023.

Based on Cresset Asset Management's 13F filing for Q1 2023, filed 12 May 2023.